Product portfolio · 2026
A portfolio ready to partner.
Alongside partner programmes, KMS develops products of its own: generic dossiers in preparation for EU, US and rest-of-world filing, and differentiated products built on reformulation, new routes and ready-to-use presentations, and a range of nutraceuticals. Each is available for licensing, co-development or supply.
- Generic dossiers in preparation
- 20
- Generic dossiers in preparation
- Differentiated products
- 17
- Differentiated products
- Nutraceuticals
- 18
- Nutraceuticals
Portfolio
Dosage form
Market
Showing 55 of 55
- SemaglutideEU/USCapsule · AntidiabeticDossier target · Jun 2027
- IbuprofenEU/USSoftgel capsule · NSAIDBE study to be done
- AlprostadilEU/USInjection · VasodilatorDossier target · Dec 2026
- Eliglustat tartrateEUCapsule · Gaucher diseaseDossier target · Jul 2027
- PivmecillinamEUTablet · AntibioticDossier target · Jul 2027
- IvermectinEUCream · AntiparasiticDossier target · Apr 2027
- LisinoprilEUTablet · AntihypertensiveDossier target · Mar 2027
- Brimonidine tartrateEU/USGel · Persistent facial erythemaDossier target · May 2027
- ApixabanEU/USTablet · AnticoagulantDossier target · Jun 2027
- Clindamycin + benzoyl peroxideEU/USTopical gel · Acne vulgarisDossier target · Jul 2027
- Sevelamer carbonateEU/USPowder for oral suspension · HyperphosphataemiaDossier target · Jul 2027
- ApremilastEU/USOral suspension · ImmunomodulatorDossier target · Jul 2027
- BrexpiprazoleEU/USTablet · Atypical antipsychoticDossier target · Aug 2027
- Ferric carboxymaltoseEU/USInjection · HaematinicDossier target · Jul 2027
- Tofacitinib citrateEU/USER tablet · ImmunomodulatorDossier ready
- Tofacitinib citrateEU/USOral solution · ImmunomodulatorDossier target · Jun 2027
- Avibactam + ceftazidimeRoWInjection · AntibioticDossier ready
- Empagliflozin + linagliptin + metforminEU/USTablet · Cardiovascular (as printed)Dossier target · Jun 2027
- RifaximinEUTablet · AntibioticDossier target · Aug 2027
- Tafluprost (preservative-free)EU/USOphthalmic solution · OphthalmicDossier target · Jun 2027
- Amlodipine—Oral solution · Antihypertensive (adults, children 6+)6-month stability completed
- Nimodipine—Oral solution · Subarachnoid haemorrhageUnder development
- Rosuvastatin—Oral suspension / solution · Hyperlipidaemia6-month stability completed
- Solifenacin succinate—Oral suspension and solution · Neurogenic detrusor overactivity (paediatric)6-month stability completed
- Deferasirox—Oral suspension · Transfusional haemosiderosis (2 years+)6-month stability completed
- Trazodone hydrochloride—Oral solution · Depression and anxietyUnder development
- Eltrombopag olamine—Ready-to-use suspension · Thrombocytopenia12-month stability completed
- Omega-3 fatty acids—Oral solution · HypertriglyceridaemiaReady for commercialisation
- Tacrolimus—Ready-to-use injectable solution · Graft-rejection prevention in HSCTReady for technology transfer
- Thiotepa—Ready-to-use injection · HSCT (as printed)Ready for technology transfer
- Triptorelin pamoate—Ready-to-use depot injection · Advanced prostate cancer (palliative)Under development
- Elagolix sodium—Extended-release tablet · Endometriosis pain (moderate to severe)Under development
- Sucroferric oxyhydroxide—Tablet (differentiated) · Hyperphosphataemia in CKDReady for technology transfer
- Rimegepant sulfate—Tablet (differentiated) · Migraine (acute treatment)Under development
- Gabapentin—Cream · Neuropathic painPOC established / under development
- Doxepin—Oral liquid (dose reduction) · Major depressive disorderPOC established / under development
- Dapsone—Topical gel (differentiated) · Acne vulgarisPOC established / under development
- Narpega-L—Oral solution (microemulsion) · Omega-3 supplementationAvailable for partnering
- Narpega-S—Soft gelatin capsule (SEDDS) · Omega-3 supplementationAvailable for partnering
- KMS Curcupi—Oral soluble tablet · Multiple ailmentsAvailable for partnering
- Ibsease—Enteric-coated pellet-filled capsule · Irritable bowel syndromeAvailable for partnering
- AFLD—Tablet · Liver fibrosisAvailable for partnering
- Drypsin—Tablet · Pain, swelling and inflammationAvailable for partnering
- KMSAC—Sachet · UTI, urinary calculi, urgency and burning micturitionAvailable for partnering
- LoHbA1c—Tablet · Diabetes managementAvailable for partnering
- Mepal—Tablet · Diabetic neuropathy and gastroparesisAvailable for partnering
- SGEN—Tablet · Sperm generation and motilityAvailable for partnering
- VbCap—Capsule (probiotic) · Bacterial vaginosisAvailable for partnering
- Cramnil—Tablet · Cramps, osteoporosis, muscle pain and arthritisAvailable for partnering
- Halitoshield—Mouth freshener · Instant mouth freshenerAvailable for partnering
- Immunobooster—Chewable tablet · ImmunityAvailable for partnering
- Ilivemet—Oral · Liver healthAvailable for partnering
- Amne-D—Orally disintegrating film · Bone healthAvailable for partnering
- Gynocare-T—Oral · Gynaecological healthAvailable for partnering
- Nutrivas—Tablet · Cardiovascular healthAvailable for partnering
Source: KMS Product List 2026, KMS Niche Product List 2026 and KMS Nutraceutical Products List. “Dossier target” is the month shown in the source list. Differentiated products show the reference product and the KMS approach.V-20 For product information or licensing, write to vasanthi@kmshc.com.
Ways to partner
Five ways to engage, one team behind each.
01
Dossier development
We develop the product and the dossier; you file it.
02
Dossier compilation
We turn development data you already hold into a submission-ready dossier.
03
Co-development
We share the development investment and the commercial return through profit sharing.
04
Technology transfer
We move a developed product into your plant or your chosen CMO.
05
Commercial supply
We supply finished product through a qualified manufacturing network.
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23